Dual antiviral therapy for HIV and hepatitis C – drug interactions and side effects

Biliography

• WHO/UNAIDS Working Group on Global HIV/AIDS and STI Surveillance. Available from: www.who.int/hiv/data/epi [Last accessed 5 June 2015]
   Google Scholar
• Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014;61(1 Suppl):45–57
   PubMed Web of Science ®Google Scholar
• Barreiro P, Fernandez-Montero JV, de Mendoza C, et al. Towards hepatitis C eradication from the HIV-infected population. Antiviral Res 2014;105:1–7
   PubMed Web of Science ®Google Scholar
• Soriano V, Labarga P, de Mendoza C, Barreiro P. Acute hepatitis C virus re-infection in a heterosexual HIV-positive partner. Liver Int 2015. [Epub ahead of print]
   Google Scholar
• Schmidt A, Rockstroh J, Vogel M, et al. Trouble with bleeding: risk factors for acute hepatitis C among HIV-positive gay men from Germany - a case-control study. PLoS One 2011;6:e17781
   PubMed Web of Science ®Google Scholar
• Sánchez C, Plaza Z, Vispo E, et al. Scaling up epidemics of acute hepatitis C and syphilis in HIV-infected men who have sex with men in Spain. Liver Int 2013;33:1357–62
   PubMed Web of Science ®Google Scholar
• Soriano V, Perelson A, Zoulim F. Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses? J Antimicrob Chemother 2008;62:1–4
   PubMed Web of Science ®Google Scholar
• Fernández-Montero JV, Vispo E, Soriano V. Emerging antiretroviral drugs. Expert Opin Pharmacother 2014;15:211–19
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services. 2015. Available from: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf [Last accessed 5 June 2015]
   Google Scholar
• European AIDS Clinical Society Guidelines. Clinical Management and Treatment of HIV Infected Adults in Europe. 7.1. 2014. Available from: www.eacsociety.org/Portals/0/GUIDELINES/ [Accessed 5th June 2015]
   Google Scholar
• Llibre JM, Clotet B. Once-daily single-tablet regimens: a long and winding road to excellence in antiretroviral treatment. AIDS Rev 2012;14:168–78
   PubMed Web of Science ®Google Scholar
• Podzamczer D, Andrade-Villanueva J, Clotet B, et al. Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study). HIV Med 2011;12:374–82
   PubMed Web of Science ®Google Scholar
• Fernandez-Montero JV, Eugenia E, Barreiro P, et al. Antiretroviral drug-related toxicities - clinical spectrum, prevention, and management. Expert Opin Drug Saf 2013;12:697–707
   PubMed Web of Science ®Google Scholar
• Lawitz E, Sulkowski M, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with HCV genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014;384:1756–65
   PubMed Web of Science ®Google Scholar
• Sulkowski M, Gardiner D, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370:211–21
   PubMed Web of Science ®Google Scholar
• Kowdley K, Gordon S, Reddy K, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879–88
   PubMed Web of Science ®Google Scholar
• Barreiro P, Labarga P, Fernandez-Montero JV, et al. Rate and predictors of serum HCV-RNA >6 million IU/mL in patients with chronic hepatitis C. Liver Int 2015; In press
   PubMedGoogle Scholar
• Molina JM, Orkin C, Iser D, et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. Lancet 2015;385:1098–106
   PubMed Web of Science ®Google Scholar
• Sulkowski M, Eron J, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA 2015;313:1223–31
   PubMed Web of Science ®Google Scholar
• Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA 2015;313:1232–9
   PubMed Web of Science ®Google Scholar
• IDSA/AASLD. Recommendations for testing, managing, and treating hepatitis C. 2015. Available from: www.hcvguidelines.org [Accessed on 5th June 2015]
   Google Scholar
• Lo Re V, Kallan M, Tate J, et al. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med 2014;160:369–79
   PubMed Web of Science ®Google Scholar
• Fernandez-Montero JV, Vispo E, Barreiro P, et al. Hepatitis delta is a major determinant of liver decompensation events and death in HIV-infected patients. Clin Infect Dis 2014;58:1549–53
   PubMed Web of Science ®Google Scholar
• Lee M, Yang H, Lu S, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 2012;206:469–77
   PubMed Web of Science ®Google Scholar
• COHERE. All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol 2012;41:433–45
   PubMed Web of Science ®Google Scholar
• EASL. Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014;60:392–420
   PubMed Web of Science ®Google Scholar
• EASL. Recommendations on treatment of hepatitis C 2015. J Hepatol 2015; In press
   Google Scholar
• Vispo E, Barreiro P, Soriano V. Pharmacokinetics of new oral hepatitis C antiviral drugs. Expert Opin Drug Metab Toxicol 2013;9:5–16
   PubMed Web of Science ®Google Scholar
• Kanda T, Nakamoto S, Wu S, Yokosuka O. New treatments for genotype 1 chronic hepatitis C - focus on simeprevir. Ther Clin Risk Manag 2014;10:387–94
   PubMed Web of Science ®Google Scholar
• You D, Pockros P. Simeprevir for the treatment of chronic hepatitis C. Expert Opin Pharmacother 2013;14:2581–9
   PubMed Web of Science ®Google Scholar
• Soriano V, Barreiro P, de Mendoza C, Peña JM. Hepatic decompensation with sofosbuvir plus simeprevir in a patient with Child-Pugh B compensated cirrhosis. Antivir Ther 2015; Epub ahead of print
   Google Scholar
• Herbst D, Reddy K. Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection. Expert Opin Investig Drugs 2013;22:527–36
   PubMed Web of Science ®Google Scholar
• Koff R. The efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther 2014;39:478–87
   PubMed Web of Science ®Google Scholar
• Stedman C. Current prospects for interferon-free treatment of hepatitis C. J Gastroenterol Hepatol 2013;28:38–45
   PubMed Web of Science ®Google Scholar
• Flisiak R, Jaroszewicz J, Parfieniuk-Kowerda A. Emerging treatments for hepatitis C. Expert Opin Emerg Drugs 2013;18:461–75
   PubMed Web of Science ®Google Scholar
• Lange C, Zeuzem S. Perspectives and challenges of interferon-free therapy for chronic hepatitis C. J Hepatol 2013;58:583–92
   PubMed Web of Science ®Google Scholar
• Gentile I, Buonomo A, Zappulo E, Borgia G. Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus free world? Expert Rev Anti Infect Ther 2014;12:763–73
   PubMed Web of Science ®Google Scholar
• Jensen D, O’Leary J, Pockros P, et al. Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: real-world experience in a diverse, longitudinal observational cohort. AASLD 2014, Boston, MA. November 7-11 2014 [abstract 45]. Hepatology 2014;60(Suppl):219A
   Google Scholar
• Dieterich D, Bacon B, Flamm S, et al. Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real world, heterogeneous population. AASLD 2014, Boston, MA. November 7-11 2014 [abstract 46]. Hepatology 2014;60(Suppl):220A
   Google Scholar
• Fazel Y, Lam B, Golabi P, Younossi Z. Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C. Expert Opin Drug Saf 2015; Epub ahead of print
   PubMedGoogle Scholar
• Bourliere M, Sulkowski M, Omata M, et al. An integrated safety and efficacy analysis of >500 patients with compensated cirrhosis treated with ledipasvir/sofosbuvir with or without ribavirin. AASLD 2014, Boston, MA [abstract 82]. Hepatology 2014;60(Suppl):239A
   Google Scholar
• Ferenci P. Treatment of hepatitis C in difficult-to-treat patients. Nat Rev Gastroenterol Hepatol 2015;12:284–92
   PubMed Web of Science ®Google Scholar
• Vidal F, Gutiérrez F, Gutiérrez M, et al. Pharmacogenetics of adverse effects due to antiretroviral drugs. AIDS Rev 2010;12:15–30
   PubMed Web of Science ®Google Scholar
• Rodriguez-Novoa S, Barreiro P, Jimenez-Nacher I, Soriano V. Overview of the pharmacogenetics of HIV therapy. Pharmacogenomics J 2006;6:234–45
   PubMed Web of Science ®Google Scholar
• Fellay J, Boubaker K, Ledergerber B, et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 2001;358:1322–7
   PubMed Web of Science ®Google Scholar
• Keiser O, Fellay J, Opravil M, et al. Adverse events to antiretrovirals in the Swiss HIV Cohort Study: effect on mortality and treatment modification. Antivir Ther 2007;12:1157–64
   PubMed Web of Science ®Google Scholar
• Barreiro P, Fernández-Montero JV, de Mendoza C, et al. Pharmacogenetics of antiretroviral therapy. Expert Opin Drug Metab Toxicol 2014;10:1119–30
   PubMed Web of Science ®Google Scholar
• Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008;358:568–79
   PubMed Web of Science ®Google Scholar
• Martin M, Klein T, Dong B, et al. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. Clin Pharmacol Ther 2012;91:734–8
   PubMed Web of Science ®Google Scholar
• Rodríguez-Nóvoa S, Cuenca L, Morello J, et al. Use of the HCP5 single nucleotide polymorphism to predict hypersensitivity reactions to abacavir: correlation with HLA-B*5701. J Antimicrob Chemother 2010;65:1567–9
   PubMed Web of Science ®Google Scholar
• Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS 2009;23:689–96
   PubMed Web of Science ®Google Scholar
• Izzedine H, Hulot J, Villard E, et al. Association between ABCC2 gene haplotypes tenofovir-induced proximal tubulopathy. J Infect Dis 2006;194:1481–91
   PubMed Web of Science ®Google Scholar
• Rodriguez-Novoa S, Labarga P, Soriano V, et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis 2009;48:e108–16
   PubMed Web of Science ®Google Scholar
• Martin A, Nolan D, James I, et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS 2005;19:97–9
   PubMed Web of Science ®Google Scholar
• Dickinson L, Chaponda M, Carr D, et al. Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi. Antimicrob Agents Chemother 2014;58:706–12
   PubMed Web of Science ®Google Scholar
• Núñez M, González-Requena D, González-Lahoz J, Soriano V. Interactions between nevirapine plasma levels, chronic hepatitis C, and the development of liver toxicity in HIV+ patients. AIDS Res Hum Retroviruses 2003;19:187–8
   PubMed Web of Science ®Google Scholar
• Maggiolo F. Efavirenz: a decade of clinical experience in the treatment of HIV. J Antimicrob Chemother 2009;64:910–28
   PubMed Web of Science ®Google Scholar
• Staszewski S, Morales-Ramirez J, Tashima K, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus Indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999;341:1865–73
   PubMed Web of Science ®Google Scholar
• Muñoz-Moreno J, Fumaz C, Ferrer M, et al. Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates and management. A neurobehavioral review. AIDS Rev 2009;11:103–9
   PubMed Web of Science ®Google Scholar
• Núñez M, González de Requena D, Gallego L, et al. Higher efavirenz plasma levels correlate with development of insomnia. J Acquir Immune Defic Syndr 2001;28:399–400
   PubMed Web of Science ®Google Scholar
• Gallego L, Barreiro P, del Río R, et al. Analyzing sleep abnormalities in HIV-infected patients treated with efavirenz. Clin Infect Dis 2004;38:430–2
   PubMed Web of Science ®Google Scholar
• Gazzard B, Balkin A, Hill A. Analysis of neuropsychiatric adverse events during clinical trials of efavirenz in antiretroviral-naive patients: a systematic review. AIDS Rev 2010;12:67–75
   PubMed Web of Science ®Google Scholar
• Rivero A, Mira J, Pineda J, et al. Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors. J Antimicrob Chemother 2007;59:342–6
   PubMed Web of Science ®Google Scholar
• Abrescia N, Abbraccio M, Figoni M, et al. Fulminant hepatic failure after the start of an efavirenz-based HAART regimen in a treatment naïve female AIDS patient without hepatitis virus co-infection. J Antimicrob Chemother 2002;50:763–5
   PubMed Web of Science ®Google Scholar
• Arnedo M, Taffe P, Sahli R, et al. Contribution of 20 single-nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy. Pharmacogenet Genomics 2007;17:755–64
   PubMed Web of Science ®Google Scholar
• Rotger M, Bayard C, Taffe P, et al. Contribution of genome-wide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals: a longitudinal study. Circ Cardiovasc Genet 2009;2:621–8
   PubMed Web of Science ®Google Scholar
• Jiménez-Nácher I, Alvarez E, Morello J, et al. Approaches for understanding and predicting drug interactions in HIV-infected patients. Expert Opin Drug Metab Toxicol 2011;7:457–77
   PubMed Web of Science ®Google Scholar
• Chtioui H, Buclin T, Moradpour D. New hepatitis C treatments: pharmacological considerations and potential for drug interactions. Rev Med Suisse 2014;10:1600–4
   PubMedGoogle Scholar
• Back D, Else L. The importance of drug-drug interactions in the DAA era. Dig Liver Dis 2013;45(Suppl 5):343–8
   PubMedGoogle Scholar
• Soriano V, Labarga P, Barreiro P, et al. Drug interactions with new hepatitis C oral drugs. Exp Opin Drug Metab Toxicol 2015;11:333–41
   PubMed Web of Science ®Google Scholar
• Soriano V, Sherman K, Rockstroh J, et al. Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus co-infected patients. AIDS 2011;25:2197–208
   PubMed Web of Science ®Google Scholar
• Seden K, Back D. Directly acting antivirals for hepatitis C and antiretrovirals: potential or drug-drug interactions. Curr Opin HIV/AIDS 2011;6:514–26
   PubMed Web of Science ®Google Scholar
• Rodriguez-Torres M. Focus on drug interactions: the challenge of treating hepatitis C virus infection with direct-acting antiviral drugs in the HIV-positive patient. Curr Opin Infect Dis 2013;26:50–7
   PubMed Web of Science ®Google Scholar
• Karageorgopoulos D, El-Sherif O, Bhagani S, Khoo S. Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/HCV coinfection. Curr Opin Infect Dis 2014;27:36–45
   PubMed Web of Science ®Google Scholar
• Burger D, Back D, Buggisch P, et al. Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. J Hepatol 2013;58:792–800
   PubMed Web of Science ®Google Scholar
• Kiser J, Burton J, Everson G. Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol 2013;10:596–606
   PubMed Web of Science ®Google Scholar
• Sarrazin C, Lathouwers E, Peeters M, et al. Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region. Antiviral Res 2015;116:10–16
   PubMed Web of Science ®Google Scholar
• Burgess S, Partovi N, Yoshida E, et al. A review of drug interactions with direct-acting antivirals for hepatitis C: implications for HIV and transplant patients. Ann Pharmacother 2015;49(6):674–87
   PubMed Web of Science ®Google Scholar
• Minaei A, Kowdley K. ABT-450/ritonavir and ABT-267 in combination with ABT-333 for the treatment of hepatitis C virus. Expert Opin Pharmacother 2015;16:929–37
   PubMed Web of Science ®Google Scholar
• Cholongitas E, Papatheodoridis G. Sofosbuvir: a novel oral agent for chronic hepatitis C. Ann Gastroenterol 2014;27:331–7
   PubMedGoogle Scholar
• Kwo P, Badshah M. New hepatitis C virus therapies: drug classes and metabolism, drug interactions relevant in the transplant settings, drug options in decompensated cirrhosis, and drug options in end-stage renal disease. Curr Opin Organ Transplant 2015;20:235–41
   PubMed Web of Science ®Google Scholar
• Soriano V, Esposito I. Caution with new oral hepatitis C drugs. AIDS Rev 2015;17:121–2
   PubMed Web of Science ®Google Scholar
• Ahmad T, Yin P, Saffitz J, et al. Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C. Hepatology 2014; In press
   Google Scholar
• Wessler J, Grip L, Mendell J, Giugliano R. The P-glycoprotein transport system and cardiovascular drugs. J Am Coll Cardiol 2013;61:2495–502
   PubMed Web of Science ®Google Scholar
• Paré G, Eriksson N, Lehr T, et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation 2013;127:1404–12
   PubMed Web of Science ®Google Scholar
• Bunchorntavakul C, Reddy K. The efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther 2015;42(3):258–72
   PubMed Web of Science ®Google Scholar
• Bifano M, Hwang C, Oosterhuis B, et al. Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir. Antivir Ther 2013;18:931–40
   PubMed Web of Science ®Google Scholar
• Alqahtani S, Afdhal N, Zeuzem S, et al. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: analysis of phase III ION trials. Hepatology 2015;62:25–30
   PubMed Web of Science ®Google Scholar
• Ray G. Antiretroviral and statin drug-drug interactions. Cardiol Rev 2009;17:44–7
   PubMed Web of Science ®Google Scholar
• Tan-Tam C, Frassetto L, Stock P. Liver and kidney transplantation in HIV-infected patients. AIDS Rev 2009;11:190–204
   PubMed Web of Science ®Google Scholar
• Falcon R, Kakuda T. Drug interactions between HIV protease inhibitors and acid-reducing agents. Clin Pharmacokinet 2008;47:75–89
   PubMed Web of Science ®Google Scholar
• Crauwels H, van Heeswijk R, Stevens M, et al. Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine. AIDS Rev 2013;15:87–101
   PubMed Web of Science ®Google Scholar
• Ripamonti D, Bombana E, Rizzi M. Rilpivirine: drug profile of a second-generation non-nucleoside reverse transcriptase HIV-inhibitor. Expert Rev Anti Infect Ther 2014;12:13–29
   PubMed Web of Science ®Google Scholar
• Reese M, Savina P, Generaux G, et al. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos 2013;41:353–61
   PubMed Web of Science ®Google Scholar
• Min S, Sloan L, De Jesus E, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS 2011;25:1737–45
   PubMed Web of Science ®Google Scholar
• Song I, Borland J, Arya N, et al. Pharmacokinetics of dolutegravir when administered with mineral supplements in healthy adult subjects. J Clin Pharmacol 2014;55(5):490–6
   PubMed Web of Science ®Google Scholar
• Dooley K, Sayre P, Borland J, et al. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr 2013;62:21–7
   PubMed Web of Science ®Google Scholar
• Coppola N, Martini S, Pisaturo MA, et al. Treatment of chronic hepatitis C in patients with HIV/HCV coinfection. World J Virol 2015;4:1–12
   PubMedGoogle Scholar
• Flanagan S, Crawford-Jones A, Orkin C. Simeprevir for the treatment of hepatitis C and HIV/hepatitis C co-infection. Expert Rev Clin Pharmacol 2014;7:691–704
   PubMed Web of Science ®Google Scholar